NCT04154787 - Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2019

Primary Completion Date

January 20, 2023

Study Completion Date

January 20, 2023

Conditions

Idiopathic Membranous Nephropathy

Interventions

DRUG

LNP023

Investigation of LNP023

DRUG

Rituximab

Comparison of rituximab dose

Trial Locations (18)

10002

Novartis Investigative Site, Taipei

12808

Novartis Investigative Site, Prague

13353

Novartis Investigative Site, Berlin

45147

Novartis Investigative Site, Essen

46017

Novartis Investigative Site, Valencia

100034

Novartis Investigative Site, Beijing

110029

Novartis Investigative Site, New Delhi

248001

Novartis Investigative Site, Dehradun

C1181ACH

Novartis Investigative Site, CABA

C1280AEB

Novartis Investigative Site, Caba

X5016KEH

Novartis Investigative Site, Córdoba

01307

Novartis Investigative Site, Dresden

07740

Novartis Investigative Site, Jena

6525 GA

Novartis Investigative Site, Nijmegen

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

LE5 4PW

Novartis Investigative Site, Leicester

NW3 2QG

Novartis Investigative Site, London

M13 9WL

Novartis Investigative Site, Manchester